About the Cover
Although immunotherapy has shown success in treating a variety of cancers, patients with pancreatic ductal adenocarcinoma (PDA) remain unresponsive to treatment, and the lack of efficient antitumor responses is not yet well understood. Mirlekar et al. establish IL35 as a driver of PDA tumor growth via suppression of T cell–mediated responses. Comparison of mice with and without this cytokine show that IL35's absence significantly reduces pancreatic tumor growth, increases tumor infiltration by CD8⁺ T cells, and improves anti–PD-1 efficacy. Thus, IL35 is a cytokine that may be targeted to improve antitumor responses in PDA, including responses to PD-1 blockade. Read more in this issue starting on page 1014. Original immunofluorescence image of human PDA from Supplementary Fig. S4C. Artwork by Lewis Long.